Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease

Eye

Volumn 23, Issue 3, 2009, Pages 543-548

  Lai, T Y Y ^a   Chan, R P S ^a   Chan, C K M ^a   Lam, D S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Corticosteroid; Panuveitis; Recurrence; Vogt Koyanagi Harada disease

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; PREDNISOLONE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; MALE; ONSET AGE; RECURRENT DISEASE; RISK FACTOR; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VOGT KOYANAGI SYNDROME; ADOLESCENT; CHILD; DRUG ADMINISTRATION; DRUG EFFECTS; EPIDEMIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROGNOSIS; UVEOMENINGOENCEPHALITIC SYNDROME; YOUNG ADULT;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CHILD; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; RECURRENCE; UVEOMENINGOENCEPHALITIC SYNDROME; VISUAL ACUITY; YOUNG ADULT;

EID: 62549147034     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.89     Document Type: Article

References (17)

1. Synder DA, Tessler HA. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1980; 90: 69-75.
2. Read RW. Vogt-Koyanagi-Harada disease. Ophthalmol Clin North Am 2002; 15: 333-341.
3. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995; 39: 265-292.
4. Sugira S. Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 1978; 22: 9-35.
5. Samamoto Y, Ohno S, Matsuda H. Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease. Ophthalmologica 1990; 201: 162-167.
6. Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy and long-term visual outcome. Arch Ophthalmol 1991; 109: 682-687.
7. Read RW, Yu F, Accorinti M, Bodaghi B, Chee SP, Fardeau C et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2006; 142: 119-124.
8. Read RW, Rechodouni A, Butani N, Johnston R, LaBree LD, Smith RE et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2001; 131: 599-606.
9. Bykhovskaya I, Thorne JE, Kempen JH, Dunn JP, Jabs DA. Vogt-Koyanagi-Harada disease: clinical outcomes. Am J Ophthalmol 2005; 140: 674-678.
10. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 2001; 131: 647-652.
11. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516.
12. Yamanaka E, Ohguro S, Yamamoto S, Nakagawa Y, Imoto Y, Tano Y. Evaluation of pulse corticosteroid therapy for Vogt-Koyanagi-Harada disease assessed by optical coherence tomography. Am J Ophthalmol 2002; 132: 454-456.
13. Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology 2007; 114: 606-614.
14. Chee SP, Jap A, Bacsal K. Spectrum of Vogt-Koyanagi-Harada in Singapore. Int Ophthalmol 2007; 27: 137-142.
15. Khairallah M, Zaouali S, Messaoud R, Chaabane S, Attia S, Ben Yahia S et al. The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa. Int Ophthalmol 2007; 27: 125-130.
16. Tugal-Tutkun I, Ozyazgan Y, Akova YA, Sullu Y, Akyol N, Soylu M et al. The spectrum of Vogt-Koyanagi-Harada in Turkey. Int Ophthalmol 2007; 27: 117-123.
17. Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D, Abu El-Asrar AM. Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol 2007; 27: 201-210.